Comparative Pharmacology
Head-to-head clinical analysis: SER A GEN versus TIMOLIDE 10 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SER A GEN versus TIMOLIDE 10 25.
SER-A-GEN vs TIMOLIDE 10-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
500 mg orally once daily.
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
None Documented
None Documented
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination